Alice Refermat
About Alice Refermat
Alice Refermat is the Director of the Center for CRISPR Target Discovery, known for her pioneering work in CRISPR technology and gene repression techniques aimed at cancer treatment.
Alice Refermat, Director of the Center for CRISPR Target Discovery
Alice Refermat serves as the Director of the Center for CRISPR Target Discovery. In this role, she leads initiatives in CRISPR cell-line engineering and CRISPR library construction. Her responsibilities include overseeing projects aimed at exploring and leveraging CRISPR technology to advance medical research and treatment.
CRISPR Cell-Line Engineering at Memorial Sloan Kettering Cancer Center
During her tenure at Memorial Sloan Kettering Cancer Center, Alice Refermat worked on critical CRISPR cell-line engineering and CRISPR library construction projects. Her contributions were vital in creating and optimizing CRISPR tools and methodologies that are essential for understanding and targeting cancer cells.
CRISPR Library Development for Druggable Genome
Alice Refermat spearheaded the effort to clone a barcoded CRISPR library for the 'druggable' genome. This initiative focused on generating a comprehensive toolset to identify and validate potential drug targets within the genome, facilitating the development of new therapeutic strategies.
Whole-Genome CRISPR Screens in Lymphoma Cell Lines
Alice Refermat completed several whole-genome CRISPR screens to uncover novel gene targets that indicate drug sensitivity in lymphoma cell lines. These screens are pivotal in identifying genetic markers that can influence the effectiveness of cancer treatments, offering insights into personalized medicine approaches.
Co-Inventor of ZFPOFF Technology for Epigenetic Gene Repression
Alice Refermat co-invented the platform technology ZFPOFF, designed for heritable epigenetic gene repression using artificial zinc-finger proteins. This innovative technology holds potential for long-term gene modulation, providing a new avenue for treating diseases with a genetic component.
Proposals for KRAS-Based Cancer Treatment Using ZFPOFF Technology
Alice Refermat proposes utilizing the ZFPOFF technology to develop a treatment for KRAS-based cancers. By leveraging the gene repression capabilities of ZFPOFF, she aims to create targeted therapies that could significantly improve outcomes for patients with these types of cancers.